个人简历

学习经历
2004.09-2008.06，中国药科大学，制药工程，学士
2008.09-2013.06，中国药科大学，药物化学，博士，导师：彭司勋、张奕华
工作经历
2013.08-2015.08，美国佛罗里达大学，博士后
2015.12-2018.12，南京医科大学，药学院，副教授，硕导
2019.01至今，江南大学，生物工程学院，副教授，硕导

研究领域

研究方向为糖类药物及长效化降糖药物研发，抗肿瘤前药设计与生物活性评价

近期论文

1. Han, J.; Meng, T.; Chen, X.; Han, Y.; Fu, J.; Zhou, F.; Fei, Y.; Li, C. The chronic administration of two novel long-acting Xenopusglucagon-like peptide-1 analogues xGLP159 and xGLP296 potently improved systemic metabolism and glycemic control in rodent models.FASEB J. 2019, accepted. (IF = 5.595)
2. Han, J.; Chen, X.; Zhao, L.; Fu, J.*; Sun, L.; Zhang, Y.; Zhou, F.; Fei, Y. Lithocholic Acid-Based Peptide Delivery System for anEnhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs. Mol. Pharm. 2018, 15, 2840-2856. (IF = 4.556)
3. Han, J.; Zhou, F.; Fei, Y.; Chen, X.; Fu, J.*; Qian, H. Preparation and Pharmaceutical Characterizations of Lipidated Dimeric XenopusGlucagon-Like Peptide-1 Conjugates. Bioconjug. Chem. 2018, 29, 390-402. (IF = 4.485)
4. Han, J.; Fei, Y.; Zhou, F.; Chen, X.; Zhang, Y.; Liu, L.; Fu, J.* Xenopus-derived glucagon-like peptide-1 and polyethylene-glycosylatedglucagon-like peptide-1 receptor agonists: long-acting hypoglycaemic and insulinotropic activities with potential therapeutic utilities. Br. J.Pharmacol. 2018, 175, 544-557. (IF = 6.81)
5. Huang, Z.; Fu, J. (co-first author); Zhang, Y., Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects. J. Med. Chem.2017, 60, 7617-7635. (IF = 6.253)
6. Han, J.; Wang, Y.; Meng, Q.; Li, G.; Huang, F.; Wu, S.; Fei, Y.; Zhou, F.; Fu, J.*, Design, synthesis and biological evaluation ofPEGylated Xenopus glucagon-like peptide-1 derivatives as long-acting hypoglycemic agents. Eur. J. Med. Chem. 2017, 132, 81-89. (IF =4.816)
7. Han, J.; Fei, Y.; Zhou, F.; Chen, X.; Zheng, W.; Fu, J.*, Micellar Nanomedicine of Novel Fatty Acid Modified Xenopus Glucagon-likePeptide-1: Improved Physicochemical Characteristics and Therapeutic Utilities for Type 2 Diabetes. Mol. Pharm. 2017, 14, 3954-3967. (IF= 4.556)
8. Han, J.; Chen, X.; Wang, Y.; Fei, Y.; Zhou, F.; Zhang, Y.; Liu, L.; Si, P.; Fu, J.*, Xenopus GLP-1-inspired discovery of novel GLP-1receptor agonists as long-acting hypoglycemic and insulinotropic agents with significant therapeutic potential. Biochem. Pharmacol. 2017,142, 155-167. (IF = 4.235)
9. Zhu, X.; Fu, J. (co-first author); Tang, Y.; Gao, Y.; Zhang, S.; Guo, Q., Design and synthesis of novel 4'-demethyl-4-deoxypodophyllotoxin derivatives as potential anticancer agents. Bioorg. Med. Chem. Lett. 2016, 26, 1360-1364. (IF = 2.454)
10. Liu, J.; Fu, J. (co-first author); Li, W.; Zou, Y.; Huang, Z.; Xu, J.; Peng, S.; Zhang, Y., Utilization of the inherent nucleophile forregioselective O-acylation of polyphenols via an intermolecular cooperative transesterification. Tetrahedron 2016, 72, 4103-4110. (IF =2.651)
11. Cui, X.; Meng, Q.; Chu, Y.; Gu, X.; Tang, Y.; Zhou, F.; Fei, Y.; Fu, J.*; Han, J., Glucagon-like peptide-1 loaded phospholipid micellesfor the treatment of type 2 diabetes: improved pharmacokinetic behaviours and prolonged glucose-lowering effects. RSC Adv. 2016, 6,94408-94416. (IF = 3.108)
12. Fu, J.; Zou, Y.; Huang, Z.; Yan, C.; Zhou, Q.; Zhang, H.; Lai, Y.; Peng, S.; Zhang, Y., Identification of nitric oxide-releasing derivativesof oleanolic acid as potential anti-colon cancer agents. RSC Adv. 2015, 5, 19445-19454. (IF = 3.289)
13. Fu, J.; Khaybullin, R.; Zhang, Y.; Xia, A.; Qi, X., Gene expression profiling leads to discovery of correlation of matrix metalloproteinase11 and heparanase 2 in breast cancer progression. BMC Cancer 2015, 15, 473. (IF = 3.265)
14. Fu, J.; Lee, T.; Qi, X., The identification of high-affinity G protein-coupled receptor ligands from large combinatorial libraries usingmulticolor quantum dot-labeled cell-based screening. Future Med. Chem. 2014, 6, 809-823. (IF = 3.744)
15. Fu, J.; Liu, L.; Huang, Z.; Lai, Y.; Ji, H.; Peng, S.; Tian, J.; Zhang, Y., Hybrid molecule from O2-(2,4-dinitrophenyl)
diazeniumdiolateand oleanolic acid: A glutathione S-transferase π-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activityand improved stability. J. Med. Chem. 2013, 56, 4641-4655. (IF = 5.48)
16. Liu, L.; Fu, J. (co-first author); Li, T.; Cui, R.; Ling, J.; Yu, X.; Ji, H.; Zhang, Y., NG, a novel PABA/NO-based oleanolic acidderivative, induces human hepatoma cell apoptosis via a ROS/MAPK-dependent mitochondrial pathway. Eur. J. Pharmacol. 2012, 691,61-68. (IF = 2.592)
17. Huang, Z.; Fu, J. (co-first author); Liu, L.; Sun, Y.; Lai, Y.; Ji, H.; Knaus, E. E.; Tian, J.; Zhang, Y., Glycosylated diazeniumdiolate-based oleanolic acid derivatives: synthesis, in vitro and in vivo biological evaluation as anti-human hepatocellular carcinoma agents. Org.Biomol. Chem. 2012, 10, 3882-3891. (IF = 3.568)